NCT07176975 2026-02-27
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Not yet recruiting
Clinical Trials
12 trialsNCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
NCT07415031 2026-02-17
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT07395258 2026-02-09
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Not yet recruiting
NCT07178938 2025-11-14
THERANOVA
MedSIR
Phase 2 Not yet recruiting
NCT06933524 2025-10-01
ATB-320-001A
Autotelicbio
Phase 1 Not yet recruiting
NCT07128576 2025-09-04
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06951425 2025-05-13
An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT06955390 2025-05-02
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
Henan Cancer Hospital
Phase 1/2 Not yet recruiting
NCT06947226 2025-04-27
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06926751 2025-04-15
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06928363 2025-04-15
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Not yet recruiting